CADTH Canadian Drug Expert Committee recommendation: Tafamidis meglumine (Vyndaqel - Pfizer Canada ULC) indication : for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary

The CADTH Canadian Drug Expert Committee (CDEC) recommends that tafamidis be reimbursed for the treatment of adult patients with cardiomyopathy due to transthyretin (TTR)-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization

Bibliographic Details

Corporate Author:	CADTH Canadian Drug Expert Committee
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH February 21, 2020, 2020
Edition:	Version 1.0
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK563410
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa